NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ELEV

Elevation Oncology Inc

Jul 14 • 04:00PM ET

0.3800

Dollar change +0.0031
Percentage change 0.82	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNS KPTI ONCY AFMD FENC MRSN ALXO MEIP CRIS RIGL

| Held by: VTI VXF VTWO IWM VTWG IWO VTWV IWN IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.81	Insider Own	10.52%	Shs Outstand	59.22M	Perf Week	0.26%
Market Cap	22.50M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	0.00%	Shs Float	53.00M	Perf Month	0.13%
Enterprise Value	-26.91M	PEG	-	EPS next Q	-0.22	Inst Own	47.02%	Short Float	3.93%	Perf Quarter	40.74%
Income	-47.99M	P/S	-	EPS this Y	8.28%	Inst Trans	-35.02%	Short Ratio	1.51	Perf Half Y	-49.59%
Sales	0.00M	P/B	0.48	EPS next Y	28.61%	ROA	-50.20%	Short Interest	2.08M	Perf YTD	-32.46%
Book/sh	0.79	P/C	0.28	EPS next 5Y	17.27%	ROE	-78.32%	52W High	3.28 -88.41%	Perf Year	-85.61%
Cash/sh	1.36	P/FCF	-	EPS past 3/5Y	17.45% -25.69%	ROIC	-61.53%	52W Low	0.22 71.95%	Perf 3Y	-74.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.10% 2.43%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	21.15%	Oper. Margin	-	ATR (14)	0.01	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.13	Recom	2.75
Dividend Gr. 3/5Y	- -	Current Ratio	19.40	EPS Q/Q	-6.28%	SMA20	0.22%	Beta	1.50	Target Price	0.39
Payout	-	Debt/Eq	0.67	Sales Q/Q	-	SMA50	8.42%	Rel Volume	1.01	Prev Close	0.38
Employees	34	LT Debt/Eq	0.67	Earnings	May 15 BMO	SMA200	-23.30%	Avg Volume	1.38M	Price	0.38
IPO	Jun 25, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.66% -	Trades		Volume	1,394,973	Change	0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-25	Downgrade	Stephens	Overweight → Equal-Weight	$5 → $1
Mar-21-25	Downgrade	Piper Sandler	Overweight → Neutral	$0.70
Mar-21-25	Downgrade	Leerink Partners	Outperform → Market Perform	$1
Mar-21-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Jan-03-25	Initiated	William Blair	Outperform
May-31-24	Initiated	Piper Sandler	Overweight	$10
May-14-24	Initiated	Stephens	Overweight	$8
Mar-01-24	Initiated	JMP Securities	Mkt Outperform	$7
May-30-23	Upgrade	SVB Securities	Market Perform → Outperform	$5 → $8
Dec-23-21	Initiated	H.C. Wainwright	Buy	$12

Jun-09-25 08:00AM	Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right (PR Newswire) +20.13%
May-15-25 07:30AM	Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates (PR Newswire) -12.24%
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
May-09-25 12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
01:25PM	Loading…
May-07-25 01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
Apr-25-25 01:00PM	Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (PR Newswire)
Apr-18-25 06:44AM	GSK prepares to relaunch Blenrep; Activists challenge another zombie biotech (BioPharma Dive)
Mar-25-25 04:30PM	Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (PR Newswire) -7.06%
Mar-21-25 01:03PM	Elevation Oncology Plunges 42% on Ending Development of Lead Drug (Zacks) +7.95%
12:01PM	Elevation Oncology downgraded as it halts lead asset on disappointing trials (Investing.com)
Mar-20-25 09:09AM	Elevation Oncology slumps on plans to drop cancer candidate (SeekingAlpha) -41.82%
08:00AM	Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options (PR Newswire)
Mar-06-25 04:30PM	Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements (PR Newswire)
07:30AM	Loading…
Feb-25-25 07:30AM	Elevation Oncology to Participate in Upcoming Investor Conferences (PR Newswire) -9.19%
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire) -6.73%
Jan-13-25 07:30AM	Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones (PR Newswire) +10.79%
Jan-07-25 09:35AM	Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-18-24 07:30PM	Bipartisan lawmakers appear 'aligned' on PBM, insurance reform (Yahoo Finance Video) -6.69%
Dec-12-24 07:30AM	Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors (PR Newswire) -7.00%
Dec-05-24 07:30AM	Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 (PR Newswire)
Nov-26-24 07:30AM	Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-06-24 07:30AM	Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Oct-10-24 12:00PM	What Makes Elevation Oncology (ELEV) a New Strong Buy Stock (Zacks)
Oct-09-24 01:02PM	Empery Asset Management's Strategic Acquisition in Elevation Oncology (GuruFocus.com)
Sep-24-24 07:31AM	FDA grants fast track designation for Elevation Oncology's EO-3021 (Pharmaceutical Business Review)
Sep-23-24 07:30AM	Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 (PR Newswire)
Sep-03-24 07:30AM	Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.89%
Aug-07-24 07:12AM	Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours (Clinical Trials Arena)
07:10AM	Loading…
Aug-06-24 07:10AM	Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements (PR Newswire) -63.37%
07:00AM	Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 (PR Newswire)
Jun-27-24 07:30AM	Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer (PR Newswire) +6.81%
May-27-24 06:35AM	7 Top Stocks to Buy for Under $10: May 2024 (InvestorPlace)
May-14-24 07:53AM	Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target (MT Newswires)
May-07-24 07:30AM	Elevation Oncology to Present at the Citizens JMP Life Sciences Conference (PR Newswire) -6.95%
May-06-24 02:06PM	How the Medical Industry Could Produce the Biggest AI Stock Winners (InvestorPlace)
May-02-24 01:54PM	ELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Apr-11-24 06:40AM	7 Top Stocks Under $7 (InvestorPlace) +7.39%
Apr-08-24 04:30PM	Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 (PR Newswire) -5.50%
Mar-28-24 01:15PM	13 Hot Stocks to Invest in According to Wall Street Analysts (Insider Monkey)
Mar-07-24 01:54PM	Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-06-24 02:51PM	ELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:30AM	Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Mar-05-24 06:00PM	Trim the Fat: 3 Overbought Stocks Poised for a Pullback (InvestorPlace)
04:50PM	Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PR Newswire)
Mar-04-24 07:30AM	Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors (PR Newswire)
Feb-28-24 07:30AM	Elevation Oncology to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-23-24 09:17AM	3 Stock Winners That Are Up 400% or More in 2024 (InvestorPlace) -5.19%
Feb-22-24 07:30AM	Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan (PR Newswire)
Jan-22-24 07:30AM	Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors (PR Newswire) +11.46%
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire) +8.84%
Jan-05-24 07:30AM	Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones (PR Newswire) +47.81%
Nov-22-23 07:30AM	Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire)
Nov-02-23 09:40AM	Elevation Oncology Inc (ELEV) Reports Q3 2023 Financial Results (GuruFocus.com)
07:30AM	Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Sep-05-23 07:30AM	Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-16-23 07:30AM	Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021 (PR Newswire) -5.10%
Aug-03-23 07:30AM	Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Jul-13-23 08:00AM	Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer (PR Newswire)
Jun-08-23 10:41PM	Elevation Oncology Announces Pricing of $50 Million Public Offering (PR Newswire) -32.27%
04:01PM	Elevation Oncology Announces Launch of Proposed Public Offering (PR Newswire)
Jun-03-23 09:00AM	Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 (PR Newswire)
May-19-23 06:54AM	Private equity firms among Elevation Oncology, Inc.'s (NASDAQ:ELEV) largest shareholders, saw gain in holdings value after stock jumped 34% last week (Simply Wall St.) -24.70%
May-15-23 07:30AM	Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Apr-26-23 04:05PM	Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 (PR Newswire) +77.19%
Apr-17-23 10:15AM	Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023 (PR Newswire)
Mar-23-23 09:40AM	Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year? (Zacks)
Mar-14-23 04:30PM	Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023 (PR Newswire) +28.83% +62.24%
Mar-09-23 07:30AM	Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
Mar-01-23 07:00AM	Elevation Oncology to Participate at Upcoming Investor Conferences (PR Newswire) +10.66%
Feb-08-23 07:00AM	Elevation Oncology to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
Jan-09-23 07:30AM	Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +6.29%
Jan-06-23 08:15AM	Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition (PR Newswire) -28.57%
Nov-30-22 07:30AM	Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-03-22 07:30AM	Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (PR Newswire) -6.47%
Aug-12-22 09:30AM	10 Best One Dollar Stocks To Buy Now (Insider Monkey)
Aug-04-22 07:30AM	Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress (PR Newswire) +9.48%
Aug-03-22 08:00AM	Elevation Oncology to Participate at the Wedbush PacGrow Healthcare Conference (PR Newswire)
Jul-28-22 08:50AM	Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures (PR Newswire) -12.77%
08:45AM	Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group (PR Newswire)
Jul-14-22 08:45AM	10 Best Penny Stocks to Buy in July (Insider Monkey)
Jun-01-22 07:30AM	Elevation Oncology to Participate at Cowen's 3rd Annual Oncology Innovation Summit (PR Newswire)
May-26-22 05:05PM	Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022 (PR Newswire) -14.97% -9.55%
08:27AM	Estimating The Intrinsic Value Of Elevation Oncology, Inc. (NASDAQ:ELEV) (Simply Wall St.)
May-25-22 07:30AM	Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions (PR Newswire) +11.93%
May-05-22 07:30AM	Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress (PR Newswire) +19.67%
Apr-27-22 10:05AM	Elevation Oncology Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022 (PR Newswire) +16.39%
Mar-24-22 01:12PM	Is Elevation Oncology (NASDAQ:ELEV) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +5.95%
Mar-14-22 07:00AM	Elevation Oncology Appoints David Dornan, Ph.D., as Chief Scientific Officer (PR Newswire) -6.36%
Mar-03-22 07:30AM	Elevation Oncology Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Mar-01-22 07:00AM	Elevation Oncology to Participate at Upcoming Virtual Investor Conferences (PR Newswire)
Jan-10-22 07:00AM	Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones (PR Newswire)
Jan-06-22 08:00AM	Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire)
Jan-05-22 08:00AM	Elevation Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-16-21 09:14AM	10 Micro-Cap Stocks to Buy According to Hedge Funds (Insider Monkey)
Nov-18-21 08:00AM	Elevation Oncology to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (PR Newswire)
Nov-12-21 07:30AM	Elevation Oncology Reports Third Quarter 2021 Financial Results (PR Newswire) -7.01%
Oct-20-21 07:00AM	Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer (PR Newswire)

Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm's program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELEV

Elevation Oncology Inc

Upgrade your FINVIZ experience